E Brignardello1, F Felicetti2,3, A Castiglione4, N Fortunati2,3, P Matarazzo5, E Biasin6, C Sacerdote4, U Ricardi7, F Fagioli6, A Corrias5, E Arvat3. 1. Transition Unit for Childhood Cancer Survivors, Department of Oncology, AOU Città della Salute e della Scienza Hospital, Via Cherasco, 15, 10126, Turin, Italy. ebrignardello@cittadellasalute.to.it. 2. Transition Unit for Childhood Cancer Survivors, Department of Oncology, AOU Città della Salute e della Scienza Hospital, Via Cherasco, 15, 10126, Turin, Italy. 3. Oncological Endocrinology Unit, Department of Oncology, University of Torino, Turin, Italy. 4. Unit of Clinical Epidemiology, University of Torino and Centre for Cancer Epidemiology and Prevention (CPO Piemonte), Turin, Italy. 5. Paediatric Endocrinology Unit, Department of Paediatric Sciences, Città della Salute e della Scienza Hospital, Turin, Italy. 6. Paediatric Hematology/Oncology Unit, Department of Paediatric Sciences, Città della Salute e della Scienza Hospital, Turin, Italy. 7. Radiation Oncology Unit, Department of Oncology, University of Torino, Turin, Italy.
Abstract
PURPOSE: Growth hormone deficiency (GHD) is the most common endocrine late effect observed in childhood cancer survivors (CCS) previously submitted to cranial irradiation. Radiation therapy can also increase the risk of second neoplasms (SNs). Since in previous studies GH replacement therapy was associated with increased incidence of neoplasia, we explored the association between SNs and GH replacement therapy in a cohort of CCS with GHD. METHODS: Within the clinical cohort of CCS referred to the Transition Unit for Childhood Cancer Survivors of Turin between November 2001 and December 2012, we considered all patients who developed GHD as a consequence of cancer therapies. GHD was always diagnosed in childhood. To evaluate the quality of data, our cohort was linked to the Childhood Cancer Registry of Piedmont. RESULTS: GHD was diagnosed in 49 out of 310 CCS included in our clinical cohort. At least one SN was diagnosed in 14 patients, meningioma and basal cell carcinoma being the most common SNs. The cumulative incidence of SNs was similar in GH-treated and -untreated patients (8 SNs out of 26 GH-treated and 6 out of 23 GH-untreated patients; p = 0.331). Age, sex and paediatric cancer type had no impact on SNs development. CONCLUSIONS: In our CCS, GH replacement therapy does not seem to increase the risk of SNs. Anyway, independently from replacement therapy, in these patients we observed an elevated risk of SNs, possibly related to previous radiation therapy, which suggests the need of a close long-term follow-up.
PURPOSE:Growth hormone deficiency (GHD) is the most common endocrine late effect observed in childhood cancer survivors (CCS) previously submitted to cranial irradiation. Radiation therapy can also increase the risk of second neoplasms (SNs). Since in previous studies GH replacement therapy was associated with increased incidence of neoplasia, we explored the association between SNs and GH replacement therapy in a cohort of CCS with GHD. METHODS: Within the clinical cohort of CCS referred to the Transition Unit for Childhood Cancer Survivors of Turin between November 2001 and December 2012, we considered all patients who developed GHD as a consequence of cancer therapies. GHD was always diagnosed in childhood. To evaluate the quality of data, our cohort was linked to the Childhood Cancer Registry of Piedmont. RESULTS: GHD was diagnosed in 49 out of 310 CCS included in our clinical cohort. At least one SN was diagnosed in 14 patients, meningioma and basal cell carcinoma being the most common SNs. The cumulative incidence of SNs was similar in GH-treated and -untreated patients (8 SNs out of 26 GH-treated and 6 out of 23 GH-untreated patients; p = 0.331). Age, sex and paediatric cancer type had no impact on SNs development. CONCLUSIONS: In our CCS, GH replacement therapy does not seem to increase the risk of SNs. Anyway, independently from replacement therapy, in these patients we observed an elevated risk of SNs, possibly related to previous radiation therapy, which suggests the need of a close long-term follow-up.
Entities:
Keywords:
Childhood cancer; Growth hormone; Radiotherapy; Second neoplasm
Authors: Aliki J Taylor; Mark P Little; David L Winter; Elaine Sugden; David W Ellison; Charles A Stiller; Marilyn Stovall; Clare Frobisher; Emma R Lancashire; Raoul C Reulen; Michael M Hawkins Journal: J Clin Oncol Date: 2010-11-15 Impact factor: 44.544
Authors: Lois B Travis; Andrea K Ng; James M Allan; Ching-Hon Pui; Ann R Kennedy; X George Xu; James A Purdy; Kimberly Applegate; Joachim Yahalom; Louis S Constine; Ethel S Gilbert; John D Boice Journal: J Natl Cancer Inst Date: 2012-02-06 Impact factor: 13.506
Authors: S Mackenzie; T Craven; H R Gattamaneni; R Swindell; S M Shalet; G Brabant Journal: J Clin Endocrinol Metab Date: 2011-06-29 Impact factor: 5.958
Authors: Renée L Mulder; Leontien C M Kremer; Hanneke M van Santen; Jan Lucas Ket; A S Paul van Trotsenburg; Caro C E Koning; Antoinette Y N Schouten-van Meeteren; Huib N Caron; Sebastian J C M M Neggers; Elvira C van Dalen Journal: Cancer Treat Rev Date: 2009-07-28 Impact factor: 12.111
Authors: Debra L Friedman; John Whitton; Wendy Leisenring; Ann C Mertens; Sue Hammond; Marilyn Stovall; Sarah S Donaldson; Anna T Meadows; Leslie L Robison; Joseph P Neglia Journal: J Natl Cancer Inst Date: 2010-07-15 Impact factor: 11.816
Authors: V Gasco; L Roncoroni; M Zavattaro; C Bona; A Berton; E Ghigo; M Maccario; S Grottoli Journal: J Endocrinol Invest Date: 2019-08-22 Impact factor: 4.256
Authors: D Ferone; E Profka; V Gasco; M R Ambrosio; A Colao; C Di Somma; E Puxeddu; G Arnaldi; C Pagano; E Zecchi; A Pietropoli; P Beck-Peccoz Journal: J Endocrinol Invest Date: 2017-02-04 Impact factor: 4.256
Authors: Matteo Spaziani; Chiara Tarantino; Natascia Tahani; Daniele Gianfrilli; Emilia Sbardella; Andrea M Isidori; Andrea Lenzi; Antonio F Radicioni Journal: Front Endocrinol (Lausanne) Date: 2021-02-24 Impact factor: 5.555
Authors: Julia Anttonen; Tiina Remes; Pekka Arikoski; Päivi Lähteenmäki; Mikko Arola; Arja Harila-Saari; Tuula Lönnqvist; Tytti Pokka; Pekka Riikonen; Kirsti Sirkiä; Heikki Rantala; Marja Ojaniemi Journal: PLoS One Date: 2022-09-06 Impact factor: 3.752
Authors: Margaret C S Boguszewski; Adriane A Cardoso-Demartini; Cesar Luiz Boguszewski; Wassim Chemaitilly; Claire E Higham; Gudmundur Johannsson; Kevin C J Yuen Journal: Pituitary Date: 2021-07-25 Impact factor: 4.107